SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (325)9/27/1999 1:14:00 AM
From: Vector1  Read Replies (1) of 666
 
rkw,
As noted by others I thought I was clear. I had not added to the CLTR position in the VD portfolio for a number of reasons. First from a portfolio management standpoint we already had a large CLTR position. Second, I stated before the refuse to file letter from the FDA that if the shorts were right and there was something wrong with the filing the stock would drop like a rock. I just did not think there was anything wrong with the filing. Boy was I wrong.
However, with the price hovering at $15 I couldn't wait any longer. See Message 11368664

I have not said much lately because while we await the refiling and ASH there is not much to say. The shorts have been right so far and I do not have any new information.

Rit is a great drug and combo therapy with CHOP is a major advance in treatment of low grade nontransformed NHL. However, there is room for Bexxar and I believe it will be approved. IF the Bexxar plus Fludarbine trials show better results than Rit plus CHOP it is a huge homerun. We will see.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News